Gossamer Bio is trading at $8.31, down -5.24%, with no company-specific announcement found to explain the October 19 decline.
- A market headline feed showed no Gossamer Bio headlines for October 19.
- Recent coverage discussed analyst views on seralutinib and the FDA review process, but identified no new October 19 catalyst.
- Major indexes were mixed or higher, which does not establish a broad-market explanation for the drop.